Allan Camaisa, Calidi Biotherapeutics CEO (via website)
June 23, 2023 10:36 AM EDTUpdated 02:19 PM
Financing

On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

Paul Schloesser

Associate Editor

Ca­li­di Bio­ther­a­peu­tics, a San Diego biotech work­ing on de­vel­op­ing al­lo­gene­ic cell de­liv­ery of on­colyt­ic virus­es, said Fri­day that in­vestors have com­mit­ted $25 mil­lion to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times